Hogan Lovells Welcomes Tao Xin as Pharma Partner, Washington DC 2026

Key Points

• Hogan Lovells has reappointed Tao Xin as a partner in its Washington office to bolster its global pharmaceuticals and biotechnology practice.
• Prior to rejoining, Tao Xin served as chair of the US healthcare and life sciences regulatory practice at Baker McKenzie.
• David Fox, practice area leader for pharmaceuticals and biotechnology at Hogan Lovells, highlighted the timing of Xin’s return as ideal for supporting clients, especially Chinese companies facing global expansion challenges.
• Tao Xin brings nearly 15 years of experience, including a prior stint at Hogan Lovells where he advanced from senior associate to counsel.
• His early career began at Keller and Heckman in Washington.
• Xin advises life sciences, food, consumer platform, and technology companies, as well as investors, on global compliance and transactions, with a focus on China-headquartered firms expanding in the Asia-Pacific.
• He holds a bachelor’s degree in biotechnology from a Chinese institution and a master’s degree in biochemistry from a US institution.
• Xin assists clients with cross-border collaborations, strategic transactions, and high-stakes US government investigations involving the US Congress, Department of Justice, and Food and Drug Administration on issues like product safety, regulatory compliance, and national security.

Washington, DC (Evening Washington News) April 30, 2026 – Hogan Lovells has welcomed back Tao Xin as a partner in its Washington office, a move that strengthens the firm’s global pharmaceuticals and biotechnology practice.

Why Has Hogan Lovells Brought Back Tao Xin to Its Washington Team?

As reported in a press release from Hogan Lovells, the firm announced Tao Xin’s return to its Washington office. Before rejoining, Xin served as chair of the US healthcare and life sciences regulatory practice at Baker McKenzie, a role he held since early 2023, according to details from Law.asia coverage of major law firm movements.

“Xin’s return comes at the perfect time,” said David Fox, practice area leader for pharmaceuticals and biotechnology at Hogan Lovells, in the firm’s press release.

“His experience guiding Chinese companies pursuing global expansion through the unique regulatory challenges they face complements our existing work and will aid our clients immensely.”

Tao Xin brings nearly 15 years of experience in the field. He was a partner at Baker McKenzie’s Washington office prior to this transition.

Earlier, he spent almost a decade at Hogan Lovells, where he progressed from senior associate to counsel. Xin began his legal career at Keller and Heckman, based in Washington.

What Expertise Does Tao Xin Offer in Pharmaceuticals and Biotechnology?

Xin advises life sciences, food, consumer platform, and technology companies, as well as investors, on global compliance and transactions.

His practice particularly focuses on companies headquartered in China or those expanding their business across the Asia-Pacific region, as noted in profiles from Law.asia and Hogan Lovells’ announcements.

Alongside his legal background, Tao holds a bachelor’s degree in biotechnology from an institution in China and a master’s degree in biochemistry from a US institution.

This scientific foundation supports his work in providing practical guidance on complex regulatory issues in these sectors.

He also assists clients in navigating legal, commercial, and cultural challenges in cross-border collaborations and strategic transactions.

How Does Tao Xin’s Experience Include US Government Investigations?

Xin’s track record includes representing international companies in high-stakes US government investigations. These proceedings have involved the US Congress, the US Department of Justice, and the US Food and Drug Administration.

The matters covered product safety, regulatory compliance, and national security issues, according to details outlined in the Hogan Lovells press release and related Law.asia reporting.

This body of work positions Xin to handle intricate matters at the intersection of regulation and international business.

Background of the Development

Hogan Lovells maintains a prominent global pharmaceuticals and biotechnology practice, with offices across key jurisdictions including Washington, DC. The firm has long advised clients on regulatory hurdles in life sciences. Baker McKenzie, where Xin previously led its US healthcare and life sciences regulatory practice, is known for its cross-border expertise, particularly in Asia-Pacific markets.

Keller and Heckman, Xin’s first firm, specialises in regulatory law for food, consumer products, and life sciences. Tao Xin’s career trajectory reflects a consistent focus on US-based regulation for international clients, especially from China, amid growing cross-border activity in biotech and pharmaceuticals.

Predictions: Impact on Clients in Pharmaceuticals and Biotechnology

This development can affect clients seeking regulatory advice in pharmaceuticals and biotechnology, particularly those based in China or the Asia-Pacific expanding globally. Firms like Hogan Lovells gain enhanced capacity to manage US regulatory challenges, including investigations by the Department of Justice, FDA, and Congress on compliance, product safety, and national security.

Chinese companies pursuing US market entry or partnerships may access more tailored guidance on cultural and commercial barriers. Investors in life sciences and technology stand to benefit from Xin’s dual legal-scientific expertise in transactions. Overall, the addition supports smoother navigation of complex, cross-jurisdictional matters for these audiences.